Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology

Area of Science:

• Oncology
• Cardiology
• Public Health

Background:

• Cardiovascular disease (CVD) and breast cancer are leading causes of morbidity and mortality in women.
• Breast cancer treatments, while improving survival, can lead to significant cardiotoxic effects.
• Survivors face long-term cardiac consequences secondary to therapy, necessitating proactive management.

Purpose of the Study:

• To highlight the cardiotoxic effects of breast cancer therapies.
• To emphasize the need for research and surveillance guidelines for CVD prevention in breast cancer survivors.
• To inform clinicians on managing cardiac risks in this patient population.

Main Methods:

• Review of existing literature on cardiotoxicity associated with breast cancer treatments.
• Analysis of the impact of anthracycline chemotherapy, trastuzumab, and radiation on cardiac function.
• Discussion of the implications for long-term cardiovascular health in breast cancer survivors.

Main Results:

• Anthracycline chemotherapy can cause left ventricular dysfunction and failure.
• Trastuzumab is associated with left ventricular dysfunction, with unclear long-term cardiac effects.
• Radiation therapy, especially for left-sided breast cancer, increases the risk of ischemic heart disease.

Conclusions:

• Long-term cardiac consequences of breast cancer therapy are a major concern for survivors.
• Identification, treatment, and prevention of therapy-induced CVD are critical.
• Further research and clear surveillance guidelines are needed for effective CVD prevention in breast cancer survivors.